Bourgeon Capital Management’s Ginkgo Bioworks DNA Stock Holding History

Bourgeon Capital Management’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,500	Closed	-$186K	–	404
2023 Q2	$186K	Sell	2,500 -8,313	-77%	-$492K	0.04%	100
2023 Q1	$575K	Buy	10,813 +125	+1%	+$7.92K	0.14%	66
2022 Q4	$722K	Buy	+10,688	New	+$983K	0.18%	65

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Bourgeon Capital Management's DNA Position: Q3 2023 in Review

Bourgeon Capital Management sold out of Ginkgo Bioworks (DNA) in Q3 2023, closing a stake of 2,500 shares — an estimated $186K sold.

Bourgeon Capital Management first reported a position in DNA in Q4 2022 and held it in 3 quarters. The position peaked at $722K in Q4 2022. 348 funds tracked by Wall St. Rank hold DNA as of Q3 2023.

Bourgeon Capital Management reported no remaining Ginkgo Bioworks position as of Q3 2023 after selling out during the quarter.
Bourgeon Capital Management sold 2,500 Ginkgo Bioworks shares in Q3 2023, an estimated $186K.
Bourgeon Capital Management first reported a position in Ginkgo Bioworks in Q4 2022 and held it in 3 quarters.
Bourgeon Capital Management's Ginkgo Bioworks position peaked at $722K in Q4 2022.
348 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2023.

Based on Bourgeon Capital Management's 13F filing for Q3 2023, filed 1 Nov 2023.